Robert Andtbacka, MD
A retrospective analysis of the phase III OPTiM study found that treatment with talimogene laherparepvec (T-VEC; Imlygic) resulted in complete responses (CR) in 17% of patients seen in all stages of melanoma. Median time to achieve a CR was 8.6 (6.0–13.6) months. A high proportion of response occurred in patients with early-stage disease and lower tumor burden, according to study authors.1
In his interview, Andtbacka explains the goals of the analysis, the significance of its results, and the future for T-VEC in melanoma.
OncLive: What prompted this analysis?
: The cutoff for the primary analysis of the OPTiM trial was in December 2012. After that cutoff, patients were followed and other secondary analyses occurred later on.
We were interested in determining if there were additional patients who had a CR with a longer follow-up, and also to try and determine what factors led them to have that CR.
What were the findings?
There were 287 patients who were treated with T-VEC. When we followed those patients after September 2014, 50 of them, or 17%, actually had a CR on the therapy. We had 43 patients, or 15%, who had a partial response (PR). Out of all the patients treated with T-VEC, 1 out of every 6 patients actually had a CR to treatment.
... to read the full story